FIELD: medicinal genetics, medicine, oncology. SUBSTANCE: invention relates to the cellular line able to express molecules inhibiting the growth of tumor in the central nervous system being this cellular line is encapsulated into immunoisolating alginate gel. The encapsulated cellular line provides a novel approach for treatment of tumors that are localized in the central nervous system, such as the brain tumors. Invention provides expanding assortment of genetic agents used for treatment of brain tumors. EFFECT: valuable medicinal properties of agent. 15 cl, 1 tbl, 7 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SATURATED ACID ANALOGS FOR CANCER TREATMENT | 2001 |
|
RU2283105C2 |
| METHOD OF SELECTING MEDICINAL PRODUCTS FOR PHARMACOLOGICAL INDUCTION OF MITOCHONDRIAL DYSFUNCTION IN MACROPHAGES FOR ANTITUMOR THERAPY | 2023 |
|
RU2810558C1 |
| METHOD OF INHIBITING MIGRATION OF CANCER CELLS | 2006 |
|
RU2404805C2 |
| MODULAR PARTICLES FOR IMMUNOTHERAPY | 2014 |
|
RU2672055C2 |
| ELUTING MATRIX AND USES THEREOF | 2013 |
|
RU2665359C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| MULTIFUNCTIONAL HYBRID RECOMBINANT PROTEIN MEDICINAL PRODUCTS FOR THE TREATMENT OF TUMOR DISEASES | 2022 |
|
RU2801367C1 |
| MONOCLONAL ANTIBODIES TO HEPATOCYTE GROWTH FACTOR | 2004 |
|
RU2361879C2 |
| ANTITUMORAL AGENT ON BASIS OF IMMUNOPOLISOME BIOLOGICAL STRUCTURE, WAY OF ITS OBTAINING AND VECTORIAL DELIVERY IN CENTRAL NERVOUS SYSTEM AT TUMORAL PROCESS | 2007 |
|
RU2336901C1 |
| HLA-DR-BINDING CHIMERIC ANTIGEN RECEPTOR AND CAR-T CELL | 2019 |
|
RU2778890C1 |
